BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 591215)

  • 1. Effect of estrogen therapy on metastatic carcinoma of the prostate.
    Anikwe RM
    Int Surg; 1977 Oct; 62(10):532-6. PubMed ID: 591215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment of cancer of the prostate.
    Madsen PO; Pedersen JF; Knuth OE
    Wis Med J; 1970 Jul; 69(7):177-81. PubMed ID: 4916084
    [No Abstract]   [Full Text] [Related]  

  • 6. [Course of prostate cancer under estrogen therapy].
    Ducassou J; Richaud C; Hermanowicz M; Fiquet JM; Alimi JC
    J Urol Nephrol (Paris); 1977; 83(1-2):91-9. PubMed ID: 875131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prelinimary report on combination therapy for advanced prostatic cancer.
    Merrin C
    Cancer Treat Rep; 1977; 61(2):313-5. PubMed ID: 559544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
    Guinan P; Firfer R; Targonski P; Rubenstein M
    Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of estrogen treatment on antithrombin III activity in patients with carcinoma of the prostate].
    Hayashi T; Takenawa J; Ryoji O; Hiura M; Taki Y; Kiriyama T
    Hinyokika Kiyo; 1989 May; 35(5):807-13. PubMed ID: 2478002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diethylstilbestrol di-trimethylacetate (DSTMA). A long-acting estrogen.
    Noland JL; Amin M
    Invest Urol; 1980 May; 17(6):506-9. PubMed ID: 7372439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer.
    Kawakami S; Takagi K; Yonese J; Ueda T; Fukui I; Kawai T
    Eur Urol; 1997; 32(1):58-63. PubMed ID: 9266233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of hormone therapy to bone metastatic prostate cancer.
    Wakisaka M; Nomura K
    Int J Urol; 2006 May; 13(5):550-4. PubMed ID: 16771724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical investigation of prostate carcinoma in the Third Teaching Hospital of Norman Bethune University of Medical Sciences].
    Xiao LS; Niu FR; Xing GJ; Fu YW; Zhao LS; Liu ZY; Znang XP
    Hinyokika Kiyo; 1988 May; 34(5):814-8. PubMed ID: 3177123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of advanced prostatic carcinoma with cis-diamminedichloroplatinum].
    Okumura S; Hasegawa J; Ohhara M; Kawamura N; Abe H; Yui Y; Kanamori S; Yoshida K; Nishimura T; Tomita M
    Hinyokika Kiyo; 1984 Dec; 30(12):1801-7. PubMed ID: 6543417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis and treatment of carcinoma of the prostate with bone metastasis].
    Kawai T; Washizuka M; Yamauchi T; Ishibashi Y; Sumi S; Kokuho M
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1704-9. PubMed ID: 3592710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.